Drug Profile

AX 2911

Alternative Names: AX-2911

Latest Information Update: 21 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProQR Therapeutics
Class Hepatoprotectants; Oligonucleotides
Mechanism of Action Adiponutrin expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Non-alcoholic steatohepatitis

Most Recent Events

12 May 2026 ProQR Therapeutics plans to initiate a first-in-human (FIH) IIT trial in the first half of 2027
11 May 2026 Pharmacodynamics data from a preclinical studies in Nonalcoholic steatohepatitis released by ProQR Therapeutics
12 Mar 2026 Pharmacodynamics data from a preclinical studies in Nonalcoholic steatohepatitis released by ProQR Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com